Sensitivity of Clinician‐Assessed Efficacy Outcome Measurement Instruments in Trials of Topical Therapies for Atopic Dermatitis: A Systematic Review and Meta‐Analysis

2021 ◽  
Author(s):  
S Légaré ◽  
M Chagnon ◽  
A Palijan ◽  
K Kojok ◽  
R Bissonnette
Keyword(s):  
Systematic Review ◽  
Atopic Dermatitis ◽  
Outcome Measurement ◽  
Meta Analysis ◽  
Measurement Instruments ◽  
Efficacy Outcome

Comparative effectiveness of probiotic strains on the prevention of pediatric atopic dermatitis: a systematic review and network meta‐analysis

2021 ◽  
Author(s):  
Carol Stephanie C. Tan‐Lim ◽  
Natasha Ann R. Esteban‐Ipac ◽  
Marysia Stella T. Recto ◽  
Mary Anne R. Castor ◽  
Roxanne J. Casis‐Hao ◽  
...  
Keyword(s):  
Systematic Review ◽  
Atopic Dermatitis ◽  
Comparative Effectiveness ◽  
Meta Analysis ◽  
Probiotic Strains

The association between atopic dermatitis and hand eczema: a systematic review and meta‐analysis

2018 ◽  
Vol 178 (4) ◽  
pp. 879-888 ◽  
Author(s):  
S.M.D. Ruff ◽  
K.A. Engebretsen ◽  
C. Zachariae ◽  
J.D. Johansen ◽  
J.I. Silverberg ◽  
...  
Keyword(s):  
Systematic Review ◽  
Atopic Dermatitis ◽  
Meta Analysis ◽  
Hand Eczema

scholarly journals Risk Factors Associated with Irreversible Airway Obstruction in Asthma: A Systematic Review and Meta-Analysis

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Lanlan Zhang ◽  
Lixiu He ◽  
Jin Gong ◽  
Chuntao Liu
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Atopic Dermatitis ◽  
Airway Obstruction ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Case Control Studies ◽  
Smoking Exposure ◽  
Asthma Patients ◽  
Irreversible Airway Obstruction

Irreversible airway obstruction (IAO) is a subtype of asthma and relates to poorer prognosis in some asthma patients. However, the prevalence and risk factors for IAO are unknown. A systematic review regarding controlled clinical studies (cohort, case-control studies) on IAO asthma in adult and/or children affected by asthma/early wheeze was performed. Eighteen papers were identified in this study. It was reported that the incidence of IAO at random effects or fixed effects in severe asthma and nonsevere asthma was 0.54 (95% CI: 0.45–0.62) and 0.16 (95% CI: 0.12–0.20), respectively. In IAO asthma, the pooled odds ratio (OR) related to smoking exposure was 2.22 (95% CI: 1.82–2.73), the OR for male, smoking, and fractional exhaled nitric oxide (FENO) was 2.22 (95% CI: 1.82–2.7), 1.79 (95% CI: 1.46–2.19), and 2.16 (95% CI: 1.05–4.43), respectively, suggesting these factors increase the risk of IAO. However, a decreased OR in IAO asthma was observed due to rhinitis (OR = 0.31, 95% CI: 0.24–0.40), atopy (OR = 0.584, 95% CI: 0.466–0.732), and atopic dermatitis (OR = 0.60, 95% CI: 0.42–0.85), indicating these factors are associated with reduced risk of IAO. IAO in asthma is associated with gender, smoking, FENO, rhinitis, atopy, and atopic dermatitis.

scholarly journals Generic Patient-Reported Outcomes and Outcome Measures: A Systematic Review Study Protocol

2021 ◽  
Author(s):  
Yuki Seidler ◽  
Erika Mosor ◽  
Margaret R Andrews ◽  
Carolina Watson ◽  
Nick Bott ◽  
...  
Keyword(s):  
Systematic Review ◽  
Outcome Measures ◽  
Systematic Reviews ◽  
Patient Reported Outcomes ◽  
Outcome Measurement ◽  
Meta Analysis ◽  
Patient Reported Outcome ◽  
Cochrane Library ◽  
Screening Process ◽  
Patient Reported

Background: Patient-reported outcomes (PROs) are an essential part of health outcome measurement and vital to patient-centricity and valued-based care. Several international consortia have developed core outcome sets and many of them include PROs. PROs are measured by patient-reported outcome measures (PROMs). PROs and PROMs can be generic or specific to certain diseases or conditions. While the characteristics of generic PROs and PROMs are well recognised as widely relevant and applicable across different domains, diseases and conditions, there is a lack of knowledge on the types of PROs measured by generic PROMs. We also do not know in which disease areas generic PROs and PROMs are commonly used. To date, there has been no systematic review solely focusing on generic PROMs, what they measure and their areas of application. Objectives: This systematic review will identify core PROs measured by generic PROMs used in adult populations and the areas in which they are applied. Methods: We will conduct a systematic review of reviews. The screening process and the reporting will comply with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) 2020 Statement. We will use four databases, Medline [PubMed], CINHAL [Ebsco], Cochrane [Cochrane Library], and PsycINFO [Ovid], and reports from international consortia. Inclusion criteria are systematic reviews, meta-analysis or patient-reported outcome sets developed by international consortia reporting on generic PROMs in adult populations. Articles primarily focusing on patient-reported experience measures (PREMs), children or adolescents, or those not written in English will be excluded. Risk of bias will be assessed by checking if the included articles comply with established guidelines for systematic reviews such as the PRISMA statement. We will extract generic PROMs and PROs measured by these PROMs, and the areas applied from the selected articles and reports. Extracted data and information will be quantitatively and qualitatively synthesised without statistical interference. The quality of the synthesised evidences will be assessed by clarifying the strengths, limitations and possible biases in our review.

The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta‐analysis

2020 ◽  
Vol 33 (4) ◽  
Author(s):  
Charan Jeet Arora ◽  
Fakhre Alam Khattak ◽  
Mohammad Tahir Yousafzai ◽  
Bukola Mary Ibitoye ◽  
Stephen Shumack
Keyword(s):  
Systematic Review ◽  
Atopic Dermatitis ◽  
Kinase Inhibitors ◽  
Meta Analysis ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document